DCGI gives nod to Bharat Biotech Intranasal 'Five Arms' COVID booster dose for restricted use

The nasal vaccine can be taken after six months of the second dose. As this is non-invasive and needle-free, it becomes easy to administer.

Published On 2022-11-26 06:00 GMT   |   Update On 2024-02-14 04:25 GMT
Advertisement

New Delhi: Vaccine manufacturer Bharat Biotech has received approval from the Drugs Controller General of India (DCGI) for an Intranasal 'Five Arms' Covid-19 booster dose for restricted use.

A source said that the emergency use authorisation (EUA) has been given to the nasal vaccine iNCOVACC for restricted emergency use as the third dose for adults irrespective of having been administered Covaxin or Covishield vaccine doses.

Advertisement

BBV154 - A novel adenovirus vectored, intranasal vaccine for COVID-19.

As per the vaccine manufacturer, the nasal route has excellent potential for vaccination due to the organised immune systems of the nasal mucosa. Thus, intranasal immunisation of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus -- thereby protecting against disease, infection, and transmission.

The nasal vaccine can be taken after six months of the second dose. As this is non-invasive and needle-free, it becomes easy to administer.

Bharat Biotech claimed that the intranasal vaccine stimulates a broad immune response. It is likely to block both infection and transmission of COVID-19.

Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus.

According to WHO, most people infected with the virus will experience mild to moderate respiratory illness and recover without requiring special treatment. However, some will become seriously ill and require medical attention. Older people and those with underlying medical conditions like cardiovascular disease, diabetes, chronic respiratory disease, or cancer are more likely to develop serious illness. Anyone can get sick with COVID-19 and become seriously ill or die at any age. 

Read also: DCGI Panel To Hold Discussion On Intranasal "Five Arms" Booster Dose INCOVACC On Nov 15: Sources

Bharat Biotech International Limited is an Indian multinational biotechnology company headquartered in Genome Valley, Turakapally, Hyderabad. The company was founded by Krishna Ella in 1996.

It is engaged in drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals, and health care products.

Read also: Scientific approach followed in Covaxin approval: Govt rebuts all allegations on Bharat Biotech Covaxin hurried approval

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News